Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 7/20 | 0.70 |
| ▸ | CTSK | P43235 | 7/20 | 0.70 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.48 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.44 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.44 |
| ▸ | REN | P00797 | 6/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.42 |
| ▸ | CTSL | P07711 | 2/20 | 0.41 |
| ▸ | CTSB | P07858 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30172531 | 0.95 | CTSS (0.76) | CTSSCTSKAAK1ITGB3ITGA2B | |
| SCHEMBL265532 | 0.88 | CTSS (0.63) | CTSSCTSKAAK1RENHDAC4 | |
| SCHEMBL28982690 | 0.86 | CTSS (0.72) | CTSSCTSKAAK1RENHDAC4 | |
| SCHEMBL28982692 | 0.86 | CTSS (0.72) | CTSSCTSKAAK1RENHDAC4 | |
| SCHEMBL3615254 | 0.83 | CTSS (0.76) | CTSSCTSKAAK1RENHDAC4 | |
| SCHEMBL3615325 | 0.83 | CTSS (0.76) | CTSSCTSKAAK1RENHDAC4 | |
| SCHEMBL3819122 | 0.81 | CTSS (0.72) | CTSSCTSKAAK1RENHDAC4 | |
| SCHEMBL8283416 | 0.80 | CTSK (0.70) | CTSSCTSKAAK1RENHDAC4 | |
| SCHEMBL9742291 | 0.80 | CTSK (0.70) | CTSSCTSKAAK1RENHDAC4 | |
| SCHEMBL482062 | 0.80 | CTSK (0.70) | CTSSCTSKAAK1RENHDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8133864-B2 | PAR-2 agonist | KOWA COMPANY, LTD. (JP) | 2012-03-13 | — | — | US | disclosed |
| EP-1864994-B1 | PAR-2 AGONIST | KOWA CO (JP) | 2011-10-26 | — | — | EP | disclosed |
| US-20090215703-A1 | PAR-2 Agonist | KOWA COMPANY, LTD. (JP) | 2009-08-27 | — | — | US | disclosed |
| EP-1864994-A1 | PAR-2 AGONIST | Kowa Company, Ltd. (JP) | 2007-12-12 | — | — | EP | disclosed |
| EP-1845104-A1 | PAR-2 AGONIST | Kowa Company. Ltd. (JP) | 2007-10-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215703-A1 | PAR-2 Agonist | FPR2, F2RL1, FPR3 | CTSS 1558/4885CTSK 2813/4885AAK1 1456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.